Ankündigung • Jun 29
ICON Public Limited Company, Annual General Meeting, Jul 31, 2026 ICON Public Limited Company, Annual General Meeting, Jul 31, 2026. Location: south county business park, leopardstown, dublin 18, Ireland Ankündigung • Jun 18
ICON Public Limited Company to Report Q1, 2026 Results on Jun 23, 2026 ICON Public Limited Company announced that they will report Q1, 2026 results After-Market on Jun 23, 2026 Ankündigung • May 31
Icon Public Limited Company Provides Earnings Guidance for the Full Year 2026 ICON Public Limited Company Provides Earnings Guidance for the Full Year 2026. For the period, the company expected revenue in the range of $7.85 billion to $8.15 billion. Ankündigung • May 30
ICON plc Announces Board Changes ICON plc announced that Mr. Kevin Egan and Mr. Jeff Elliott will join ICON's Board of Directors, effective June 1, 2026 and that Dr. Steve Cutler resigned from the Board effective May 21, 2026. Mr. Kevin Egan brings a wealth of experience, notably in auditing, after completing a 37-year career in public auditing, including leading PwC Ireland's audit and assurance practice from 2007 - 2015. He also currently serves as non-executive director and Chair of the Audit Committee at Perrigo plc. Mr. Jeff Elliott also brings a significant amount of expertise and financial depth, from previous leadership and operational roles. He was Chief Financial Officer of Exact Sciences Corp. from 2016 to 2024, and also served as Chief Operating Officer from 2021 to 2023. Prior to his roles at Exact Sciences, Jeff was a senior equity research analyst covering healthcare companies at Robert W. Baird & Co. Additionally, Jeff currently serves as non-executive director on the Boards of Quanterix Inc. and Sera Prognostics. Ankündigung • May 27
ICON Public Limited Company to Report Q4, 2025 Results on May 27, 2026 ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on May 27, 2026 Ankündigung • May 03
ICON Public Limited Company announced delayed 20-F filing On 05/01/2026, ICON Public Limited Company announced that they will be unable to file their next 20-F by the deadline required by the SEC. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to Mex$1,850, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 21x in the Life Sciences industry globally. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,096 per share. Ankündigung • Mar 11
An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC. An undisclosed buyer acquired an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025.
An undisclosed buyer completed the acquisition of an unknown minority stake in ICON Public Limited Company (NasdaqGS:ICLR) from Polen Capital Management, LLC on December 31, 2025. Ankündigung • Feb 12
ICON Public Limited Company to Report Q4, 2025 Results on Apr 30, 2026 ICON Public Limited Company announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2026 Ankündigung • Dec 09
ICON plc Releases Findings from Two Biotech Sector Survey ICON plc released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East. ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&D priorities since its last survey in 2023. It positions China's presence as a positive signal for the global industry, with the findings highlighting how Western biotechs must adapt to maintain competitiveness and drive innovation. Funding remains a key challenge and 41% of organizations are actively seeking additional R&D funding, a 27% increase since 2023, highlighting ongoing financial pressures across the industry. Globally, the top three sources of funding are unchanged: large pharma partnerships, venture capital (VC), and government grants. However, the survey shows how VC funds have expanded their focus, with APAC biotechs stating VC funding was 60% of their current funding source versus 32% for US and 30% for Europe. This is leading some biotechs to explore innovative funding sources and ICON highlights the emerging models being increasingly adopted, including royalty financing, carve-outs, and crowdfunding. Since the last survey, access to talent is becoming more of a concern. This was more pronounced in APAC where responders were almost three times as likely to list talent shortages as having operational impact as their global counterparts (47% vs 18% in the US and 17% in Europe). The survey reveals leading next-generation modalities; notably, cell therapy has overtaken small molecules and is now most prominent, making up 40% of organizations' pipelines. Antibody drug conjugates (ADCs) and microbiome therapies are not far behind at 31%. Therapeutic focus areas have also evolved since the last survey findings, with neurology (44%), cardiovascular (39%), and immune disorders (32%) now outpacing a previous dominance in oncology. Despite the multiple macro challenges they face, the biggest risk to biotechs' operations is the complexity of drug development. Almost three quarters of respondents (73%) ranked this among their top five micro factorsposing the greatest risk to their organisation's operations. The survey highlighted how biotech companies are increasingly embracing digital technologies to improve operations, with 76% of respondents anticipating AI and other technologies will significantly accelerate R&D processes within the next two years. When asked which factors have the most potential to accelerate drug development, 41% of respondents selected AI-enabled asset selection in drug discovery, an increase from 26% in 2023. ION's separate survey of China-based biotechs, was based on 100 respondents. The findings highlighted that the challenges China-based biotechs face align with their global counterparts, most notably funding, and the complexity of drug development and regulations. Cardiovascular and oncology remain the top therapeutic focus areas in China, in contrast to the global shift toward neurology. However, cell therapy, microbiome therapies, and ADCs dominate pipelines across all regions. Respondents in China also report less concern about geopolitical developments and greater confidence in investment and product success. Ankündigung • Dec 02
Icon plc Announces Results of Its Latest Industry Survey ICON plc announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered perspectives from a wide range of clinical trial sites and is not limited to studies managed by ICON. It reveals widespread sentiment that sites are increasingly burdened by operational bottlenecks, contract and budget delays, and communication gaps. These challenges contribute to significant disruptions at the startup stage, with 55% of respondents reporting that time from site selection to full activation is longer than 5 months, and 39% reporting longer timelines than two years ago. Contract and budget delays are a persistent issue, with 66% of respondents experiencing them frequently. Almost all respondents (92%) identified these as the top areas where both sponsors and contract research organizations (CROs) can improve support. With 47% of respondents rating sponsor and CRO communication as average or poor, this highlights a critical need for site-centricity. Board Change • Sep 29
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 24
ICON Public Limited Company to Report Q3, 2025 Results on Oct 22, 2025 ICON Public Limited Company announced that they will report Q3, 2025 results After-Market on Oct 22, 2025 Ankündigung • Sep 22
ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD) ICON Public Limited Company(NasdaqGS:ICLR) dropped from FTSE All-World Index (USD) Board Change • Sep 05
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Jul 24
ICON Public Limited Company Updates Earnings Guidance for Full Year 2025 ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company updates full-year financial guidance and now expect full-year revenue to be in the range of $7,850 million - $8,150 million, an increase of approximately 1% at the midpoint from prior full-year revenue guidance range. Ankündigung • Jun 23
ICON Public Limited Company to Report Q2, 2025 Results on Jul 23, 2025 ICON Public Limited Company announced that they will report Q2, 2025 results After-Market on Jul 23, 2025 Ankündigung • Jun 12
ICON Public Limited Company, Annual General Meeting, Jul 22, 2025 ICON Public Limited Company, Annual General Meeting, Jul 22, 2025. Location: south county business park, leopardstown., dublin 18 Ireland Ankündigung • May 01
Icon Public Limited Company Updates Earnings Guidance for Full Year 2025 ICON Public Limited Company updated earnings guidance for full year 2025. For the period, the company Updated full-year 2025 financial revenue guidance in the range of $7,750 - $8,150 million, representing a year - over - year decrease of -6.4% to -1.6%. Ankündigung • Mar 31
ICON Public Limited Company to Report Q1, 2025 Results on Apr 30, 2025 ICON Public Limited Company announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 30, 2025 Ankündigung • Feb 22
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2025 ICON Public Limited Company Reaffirmed earnings guidance for the year 2025. The company is re-affirming previously communicated full-year 2025 financial revenue guidance in the range of $8,050 million - $8,650 million. Ankündigung • Feb 20
ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $750 million worth of its shares. ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its shares. Ankündigung • Feb 12
Robbins LLP Announces Class Action Lawsuit Against ICON PLC Robbins LLP informed stockholders that a class action was filed on behalf of all purchasers of ICON PLC ordinary shares between July 27, 2023 and October 23, 2024. The Allegations: Robbins LLP is Investigating Allegations that ICON PLC (ICLR) Misled Investors Regarding Demand. According to the complaint, during the class period, defendants failed to disclose that: (a) ICON was suffering from a material loss of business due to customer cost reduction measures and other widespread funding limitations impacting the Company's client base; (b) ICON's purported FSP and hybrid model offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the RFPs ICON received from its biotechnology customers during the class period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand; (d) ICON's customers had canceled contracts, limited or reduced engagements, delayed clinical trial work, and/or failed to enter into new contracts with ICON for additional clinical trial work at historical rates once existing projects ended (or were scheduled to end) in 2024; (e) ICON's two larger customers were diversifying their CRO providers away from the Company; (f) as a result of (a)-(e) above, ICON's reported net new business awards and book-to-bill metrics materially misrepresented client demand for ICON's services; and (g) that as a result of (a)-(f) above, ICON was tracking materially below the 2024 revenue and EPS guidance issued during the class period and such guidance lacked a reasonable factual basis. Ankündigung • Jan 30
Icon Portfolio of Ai Tools Drives Clinical Trial Efficiencies ICON plc announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting. ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI solutions that accelerate trials, enhance data and optimise operational efficiencies. The centre is supported by an AI Governance Committee, which oversees ethical, legal and data privacy standards in the deployment of new solutions. The latest solutions to be launched are: Submit, which automates the clinical trial document management process. It uses AI to improve compliance, reduce the burden on clinical project teams, and manage documents in an efficient and accurate way based on defined rules. Mapi Research Trust COA leverages AI to remain current with latest Clinical Outcome Assessments (COAs) from public sources in near real-time. It provides comprehensive intelligence to support optimal clinical trial protocols/designs. FORWARD+ is an AI-enabled capability that provides industry-leading visibility into resource demands, allocations and forecasting. FORWARD+ ensures efficient resource management through the clinical trial process. Study Start-up Site Contracts is an AI-enabled capability that streamlines the clinical contract drafting process by leveraging historical clinical contracts in order to create comprehensive near final draft contracts. OMR AI Navigation Assistant empowers operational clinical study metrics with generative AI to provide industry-leading analytics to transform data into business insights. Based on its success to date in implementing innovative AI solutions for its customers, ICON plans to further enhance its award-winning capabilities in how AI can drive productivity and efficiencies in clinical trials, with support from Enterprise Ireland. This sustained focus on investment in AI solutions by ICON will support its customers as they look to overcome some of the challenges in realising the potential of AI in drug development. A recent ICON survey of biopharma companies found that 13% of respondents indicated that while AI and digital technologies are being heavily used in single development programs, it is challenging for organizations to systemically incorporate them, possibly due to the complexity of managing such strategic, enterprise-scale digital disruption. Ankündigung • Jan 29
ICON Public Limited Company to Report Q4, 2024 Results on Feb 19, 2025 ICON Public Limited Company announced that they will report Q4, 2024 results After-Market on Feb 19, 2025 Ankündigung • Jan 15
ICON Public Limited Company Reaffirms Earning Guidance for the Full Year 2024 and Provides Earning Guidance for the Full Year 2025 ICON Public Limited Company reaffirmed earning guidance for the full year 2024 and provided earning guidance for the full year 2025. For the full year 2024 the company reaffirms its current guidance of revenue in the range of $8,260million to $8,300 million.
For the full year 2025, the company is expected revenue to be in the range of $8,050 million to $8,650 million, representing growth of approximately 1% at the midpoint. Ankündigung • Jan 08
Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative Disorders ICON plc released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: 'Early, precise and efficient: The methods and technologies advancing Alzheimer's and Parkinson's R&D'. Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (97%) reported using biomarkers to identify patients and over half (59%) are leveraging AI tools to accelerate biomarker detection. Whilst this uptake is promising, biomarkers are not yet being optimised for full implementation. The use of biomarkers can sometimes make a trial longer, more expensive, and slower to enrol patients. However, implementation of biomarker tests could be increasingly implemented to address some of the more resource-intensive eligibility criteria, such as imaging or CSF status. Innovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only 28% of respondents reported implementing an adaptive trial design of any type, while even fewer reported using historic controls (22%) or master protocol designs (19%), all of which can accelerate patient recruitment. Encouragingly, the survey revealed sponsors are not deterred from investing in R&D, especially in a diversified way. A large majority of respondents (87%) reported that they plan to invest in multiple therapeutic areas or a combination approach. They are also using AI to accelerate R&D, predominantly for the initial steps of the development process. For example, half of respondents who reported using AI or machine learning employ it for hypothesis generation (48%) and lead discovery (50%). Interestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only 29% of respondents indicated that it was an area that could support and accelerate R&D. Ankündigung • Dec 18
ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer ICON plc announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to customers and further enhance the company's strategy to become the healthcare intelligence partner of choice in the industry. Barry will continue to report to ICON’s Chief Executive Officer, Steve Cutler. Ankündigung • Oct 25
ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares. ICON Public Limited Company (NasdaqGS:ICLR) announces a share repurchase program. Under the program, the company will repurchase up to $250 million worth of its shares. Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: US$2.38 (vs US$1.99 in 3Q 2023) Third quarter 2024 results: EPS: US$2.38 (up from US$1.99 in 3Q 2023). Revenue: US$2.03b (down 1.2% from 3Q 2023). Net income: US$197.1m (up 20% from 3Q 2023). Profit margin: 9.7% (up from 8.0% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Ankündigung • Oct 24
ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024 ICON Public Limited Company updated earnings guidance for the full year 2024. For the period, the company is updating full-year 2024 financial revenue guidance in the range of $8,260 million - $8,300 million, representing a year over year increase of 1.7% to 2.2%. Board Change • Oct 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Anne Michelle Whitaker was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 27
ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024 ICON Public Limited Company announced that they will report Q3, 2024 results After-Market on Oct 23, 2024 Ankündigung • Aug 15
ICON plc Announces Chief Financial Officer Changes ICON plc announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare’s CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes and oversaw strong financial growth across multiple business lines. Most recently, Nigel was CFO at LetsGetChecked, a global provider of at-home healthcare services. Nigel has a long tenure and a strong track record of success as CFO in a number of large organizations in the life sciences and healthcare services industry. He has successfully led and supported the financial growth of a number of organizations and has a strong background as a CFO of a public company with significant experience in M&A as well as financial processes and systems enhancement. Nigel holds a Bachelor of Science (Accounting) degree and a Master of Accounting degree from Queen’s University Belfast and is also a qualified chartered accountant and a fellow of Chartered Accountants Ireland. Nigel will be based in ICON’s Dublin office and will join ICON early in quarter four this year. The company tanks to its outgoing CFO, Brendan Brennan, for his significant contribution to ICON over the past 18 years. Ankündigung • Jul 25
ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024 ICON Public Limited Company updated earnings guidance for the full-year 2024. The company updating full-year 2024 financial revenue guidance in the range of $8,450 to $8,550 million, representing a year over year increase of 4.1% to 5.3%. Ankündigung • Jul 24
ICON Public Limited Company Announces Board Changes ICON Public Limited Company confirmed that following the conclusion of the company's AGM, Joan Garahy retired as a non-executive director and announced that Anne Whitaker was appointed as a non-executive director, at its AGM held on July 24, 2024. Ms. Whitaker is an experienced healthcare executive, advisor and director. She currently serves as managing partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, CEO and Chair of the Board of Aerami Therapeutics, and as an operating partner of NewVale Capital, a private equity firm. Ms. Whitaker was previously CEO and director of Novoclem Therapeutics. Earlier in her career, Ms. Whitaker held senior executive leadership positions at Bausch Health, Sanofi, GlaxoSmithKline, and multiple CEO roles for private and public development-stage companies. Ms. Whitaker serves as the Chair of QurAlis and as a non-executive director of Nykode Therapeutics, Trinity Life Sciences, Byrn Pharma and Bespak. She is a member of the Board of Trustees of the University of North Alabama. She previously served on the boards of Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Cree, Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group and Synta Pharmaceuticals. She holds a BSc in Chemistry and Business from the University of North Alabama. Ankündigung • Jul 02
ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024 ICON Public Limited Company announced that they will report Q2, 2024 results After-Market on Jul 24, 2024 Ankündigung • Jun 13
ICON Public Limited Company, Annual General Meeting, Jul 23, 2024 ICON Public Limited Company, Annual General Meeting, Jul 23, 2024. Location: south county business park, leopardstown, dublin 18 Ireland Ankündigung • May 31
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024 ICON Public Limited Company reaffirmed earnings guidance for the year 2024. Full-year 2024 revenue guidance is reaffirmed in the range of $8,480 million - $8,720 million, representing a year over year increase of 4.4% to 7.4%. Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: US$2.27 (vs US$1.43 in 1Q 2023) First quarter 2024 results: EPS: US$2.27 (up from US$1.43 in 1Q 2023). Revenue: US$2.09b (up 5.7% from 1Q 2023). Net income: US$187.4m (up 61% from 1Q 2023). Profit margin: 9.0% (up from 5.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Global Life Sciences industry. Board Change • Apr 25
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Mar 26
ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024 ICON Public Limited Company announced that they will report Q1, 2024 results After-Market on Apr 24, 2024 Ankündigung • Jan 31
ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024 ICON Public Limited Company announced that they will report Q4, 2023 results After-Market on Feb 21, 2024 Board Change • Jan 11
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Jan 10
ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024 ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024. For the period, the company expected revenue in the range of $8,070 million - $8,210 million and adjusted earnings per share1in the range of $12.63- $12.91.For the year, the company expects revenue guidance in the range of $8,400 million - $8,800 million, representing growth of 3.2% – 8.1% over Full Year 2023 Revenue guidance midpoint. Board Change • Nov 17
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 28
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Ankündigung • Sep 22
ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023 ICON Public Limited Company announced that they will report Q3, 2023 results After-Market on Oct 25, 2023 Ankündigung • Sep 21
ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution ICON plc announced the release of its next generation Clinical Trial Tokenisation solution. The combination of ICON's proprietary tokenisation engine, access to real-world data and advanced clinical analytics expertise, now delivered through a cohesive and seamless operational model, provides valuable, long-term insights on drug safety and efficacy, throughout the product development lifecycle. ICON's next generation proprietary Clinical Trial Tokenisation solution seamlessly integrates all the necessary components to allow for the collation of patient data in a consented, discreet and non-intrusive way with Privacy Protected Record Linkage (PPRL) across time and source. Furthermore, ICON's capability to generate multiple tokens, coupled with advanced analytics, provides highly accurate matching (up to 90%) of clinical trial participants to the ecosystem of real-world data sources in the United States. This enables the best available secondary data to be used, resulting in enhanced evidence generation in a highly cost and time efficient manner for customers, with robust protection of patient privacy. Valuable insights from this offering can be leveraged in many ways, including regulatory and reimbursement discussions and scientific publications to optimise clinical development lifecycles. This can also be used to better understand the response of specific sub-cohorts of patients, and to conduct long-term safety surveillance. ICON's Clinical Trial Tokenisation solution is delivered within an operating framework aligned to industry security and data privacy standards, and its corporate security and data protection programs have been assessed to ISO 27001 and 27701 standards. ICON is uniquely positioned to support customers because, in addition to commercialisation capability, it has extensive experience in clinical research, regulatory management, and healthcare intelligence, all crucial to clinical trial tokenisation. Ankündigung • Sep 14
ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial ICON plc announced that it is partnering with the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to execute a clinical trial to evaluate the effectiveness of next generation COVID-19 vaccine candidates. Next generation COVID-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of the virus, extend the duration of protection, and offer better protection in the prevention of illness and transmission over the current state of vaccine technologies. Against this backdrop, the Government & Public Health Solutions team at ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infection. The trial will involve 10,000 subjects, expected to be enrolled over a six-month period. BARDA will select the vaccine candidate to be investigated in this trial, thereby accelerating the start of the Phase 2b clinical trial to support in benchmarking its efficacy against existing vaccines. ICON has extensive experience in vaccine clinical development for commercial businesses, governments and NGOs, having participated in over 184 vaccine studies in the past five years. This experience has already helped ICON play a significant role in the search for vaccines and treatments for COVID-19. The company has partnered with its customers on the development of a number of approved vaccines. ICON has conducted or is currently involved in over 86 COVID-19 related trials. In addition to its Government & Public Health Solutions team, ICON draws on the expertise of its biotech division, which comprises over 8,000 staff dedicated to biotech customers. As the world’s largest dedicated biotech division, the team works with over 500 biotech sponsors annually. This trial is part of Project NextGen, which coordinates across the U.S. Government and the private sector to advance innovative vaccines and therapeutics into clinical trials, regulatory review, and potential commercial availability. BARDA is responsible for developing medical countermeasures to secure the U.S. against chemical, biological, radiological, and nuclear threats, as well as pandemic influenza and emerging infectious diseases. Since 2014, ICON has been a member of BARDA’s Medical Countermeasures Clinical Studies Network (CSN). The network supports planning and implementation of clinical studies for medical countermeasure development. ICON has worked on numerous clinical trials as part of this network, including, most recently, the execution of an anthrax vaccine clinical trial. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50120D00017. Ankündigung • Jun 28
ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023 ICON Public Limited Company announced that they will report Q2, 2023 results After-Market on Jul 26, 2023 Ankündigung • Jun 13
ICON Public Limited Company, Annual General Meeting, Jul 25, 2023 ICON Public Limited Company, Annual General Meeting, Jul 25, 2023, at 08:30 Coordinated Universal Time. Location: ICON's global headquarters in South County Business Park, Leopardstown Dublin 18 Ireland Agenda: To consider reelection of directors; to review the Company's affairs and consider ICON's 2022 accounts which have been audited by KPMG, ICON's independent auditors; to authorize the Directors to fix the remuneration of the auditors; to consider authority to issue shares up to 20% of share capital; to consider authority to issue shares up to 20% of share capital without offering to existing shareholders; to consider authority to buy back shares up to 10% of share capital; to transact other business. Reported Earnings • Apr 29
First quarter 2023 earnings released: EPS: US$1.43 (vs US$1.37 in 1Q 2022) First quarter 2023 results: EPS: US$1.43 (up from US$1.37 in 1Q 2022). Revenue: US$1.98b (up 4.0% from 1Q 2022). Net income: US$116.7m (up 4.2% from 1Q 2022). Profit margin: 5.9% (in line with 1Q 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Global Life Sciences industry. Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to Mex$3,703, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 33x in the Life Sciences industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$3,833 per share. Board Change • Apr 20
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 24
Full year 2022 earnings released: EPS: US$6.20 (vs US$2.28 in FY 2021) Full year 2022 results: EPS: US$6.20 (up from US$2.28 in FY 2021). Revenue: US$7.74b (up 41% from FY 2021). Net income: US$505.3m (up 230% from FY 2021). Profit margin: 6.5% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Global Life Sciences industry. Ankündigung • Jan 27
ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023 ICON Public Limited Company announced that they will report Q4, 2022 results After-Market on Feb 22, 2023 Ankündigung • Jan 11
Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023 ICON Public Limited Company reaffirmed revenue guidance for full year 2022 and provided revenue guidance for full year 2023. For full year 2022, the company reaffirmed its current guidance of revenue in the range of $7,690 - $7,810 million. For the full year 2023, revenue is expected to be in the range of $7,940 - $8,340 million, representing growth of 3.3% – 6.8%, and adjusted earnings per share1 is expected to be in the range of $12.40 – $13.05, representing growth of 6.4% – 10.1%, over Full Year 2022 revenue. Board Change • Jan 11
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 2 highly experienced directors. Independent Director Lind Grais was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 03
Third quarter 2022 earnings released: EPS: US$1.96 (vs US$1.17 loss in 3Q 2021) Third quarter 2022 results: EPS: US$1.96 (up from US$1.17 loss in 3Q 2021). Revenue: US$1.94b (up 4.1% from 3Q 2021). Net income: US$160.2m (up US$254.4m from 3Q 2021). Profit margin: 8.2% (up from net loss in 3Q 2021). Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Global Life Sciences industry. Reported Earnings • Jul 28
Second quarter 2022 earnings released: EPS: US$1.42 (vs US$1.40 in 2Q 2021) Second quarter 2022 results: EPS: US$1.42 (up from US$1.40 in 2Q 2021). Revenue: US$1.94b (up 122% from 2Q 2021). Net income: US$115.7m (up 57% from 2Q 2021). Profit margin: 6.0% (down from 8.5% in 2Q 2021). Over the next year, revenue is forecast to grow 7.3%, compared to a 12% growth forecast for the industry in Mexico. 
